Search

Displaying results 5251 - 5260 of 7186 in total
  1. Drug

    beta-Alanine

    go.drugbank.com/drugs/DB03107
    Investigational

    Since neuronal uptake and neuronal receptor sensitivity to beta-alanine have been demonstrated, the compound may be a false transmitter replacing GAMMA-AMINOBUTYRIC ACID. … beta-Alanine is an amino acid formed in vivo by the degradation of [dihydrouracil] and [carnosine].

  2. Drug

    CIGB 300

    go.drugbank.com/drugs/DB16464
    Investigational

    CIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma

  3. Drug

    RTP-801i

    go.drugbank.com/drugs/DB06048
    Investigational

    RTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801.

  4. Drug

    Curcumin sulfate

    go.drugbank.com/drugs/DB14635
    Experimental

  5. Drug

    TT 173

    go.drugbank.com/drugs/DB17717
    Investigational

    TT 173 is a Modified Human Tissue Factor currently being investigated to treat bleeding disorders such as hemophilia and von Willebrand disease, as well as bleeding episodes in cutaneous injuries or dental

  6. Drug

    Exbivirumab

    go.drugbank.com/drugs/DB17747
    Experimental

    It is one of the active ingredients in HepeX-B, a drug product containing two human monoclonal antibodies to the hepatitis B virus (HBV) surface antigen.[A259202]

  7. Drug

    AG-858

    go.drugbank.com/drugs/DB05502
    Investigational

    Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models.

  8. Drug

    Patupilone

    go.drugbank.com/drugs/DB03010
    Investigational

    Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol.

  9. Drug

    V590

    go.drugbank.com/drugs/DB16437
    Experimental

    Merck is currently underway to begin Phase I trials for the vaccine through intramuscular administration (NCT04569786). … The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®[A226818, L30573, L30578].

  10. Drug

    Melperone

    go.drugbank.com/drugs/DB09224
    Investigational

    Recently, it has been studied as a treatment of psychosis related to Parkinson's disease [L1316]. … Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol.